Could Ginkgo Bioworks Holdings Inc (DNA) stock price achieve new all-time highs if its expected earnings and revenue increase?

Stocks of Ginkgo Bioworks Holdings Inc (NYSE:DNA) traded higher last session on Wall Street, down -7.32% to $1.52.

According to the data, Ginkgo Bioworks Holdings Inc (NYSE:DNA) has 9 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $12.00 and a low of $1.25, we find $3.20. Given the previous closing price of $1.64, this indicates a potential upside of 95.12 percent. DNA stock price is now -14.40% away from the 50-day moving average and -9.35% away from the 200-day moving average. The market capitalization of the company currently stands at $3.01B.

A total of 2 analysts have issued a hold rating and 4 have given it a buy rating. Brokers who have rated the stock have averaged $4.02 as their price target over the next twelve months.

With the price target reduced from $3 to $1.25, Goldman Downgraded its rating from Neutral to Sell for Ginkgo Bioworks Holdings Inc (NYSE: DNA).

In other news, Kelly Jason R, insider sold 100,000 shares of the company’s stock on Nov 02. The stock was sold for $151,600 at an average price of $1.52. Upon completion of the transaction, the insider now directly owns 5,494,680 shares in the company, valued at $8.35 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 02, 10% Owner Canton Barry sold 37,650 shares of the business’s stock. A total of $57,077 was realized by selling the stock at an average price of $1.52. This leaves the insider owning 12,638,094 shares of the company worth $19.21 million. Insiders disposed of 39,114,075 shares of company stock worth roughly $59.45 million over the past 1 year. A total of 35.84% of the company’s stock is owned by insiders.

Monday’s opening bell rang with an opening price of $1.6600 for Ginkgo Bioworks Holdings Inc (NYSE: DNA). During the past 12 months, Ginkgo Bioworks Holdings Inc has had a low of $1.12 and a high of $2.94. As of last week, the company has a debt-to-equity ratio of 0.27, a current ratio of 7.49, and a quick ratio of 7.49. The fifty day moving average price for DNA is $1.7756 and a two-hundred day moving average price translates $1.6767 for the stock.

The latest earnings results from Ginkgo Bioworks Holdings Inc (NYSE: DNA) was released for Jun, 2023. The net profit margin was -375.48% and return on equity was -80.54% for DNA. The company reported revenue of $80.57 million for the quarter, compared to $144.62 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -44.29 percent.

Ginkgo Bioworks Holdings Inc(DNA) Company Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Related Posts